- Home
- KRON
KRON
Kronos Bio Inc.
as 02-21-2025 4:00pm EST
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 61.5M | IPO Year: | 2020 |
| Target Price: | $1.63 | AVG Volume (30 days): | 223.2K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $1.60 | Next Earning Date: | 03-20-2025 |
| Revenue: | $9,864,000 | Revenue Growth: | 146.48% |
| Revenue Growth (this year): | 62.21% | Revenue Growth (next year): | N/A |
Latest Kronos Bio Inc. News
KRON Breaking Stock News: Dive into KRON Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
MT Newswires
2 months ago
Kronos Bio, Genentech to Terminate Research Partnership; Shares Down Pre-Bell
Simply Wall St.
3 months ago
Discover 3 US Penny Stocks With Market Caps Over $40M
Pharmaceutical Technology
3 months ago
Kronos Bio announces interim CEO and workforce cuts of 83%
Benzinga
3 months ago
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul
MT Newswires
3 months ago
Kronos Bio Names Deborah Knobelman Interim CEO, Cuts Workforce by 83%
GlobeNewswire
3 months ago
Kronos Bio Announces CEO Transition and Reduction in Force
BioPharma Dive
3 months ago
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Compare KRON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRON Kronos Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.